This project platform will mitigate current drug-based treatments' limitations by avoiding off-target and systemic side effects while providing a novel, scalable approach to clinical applications with…

Active Cooperative Agreement Awarded Last action

Award ID
D26AC50003
Recipient
Awarding agency
Obligated
$7,620,641

Award facts

Completion date 49% complete
Place of performance
La Jolla, CA 92037, USA

Award details come from USAspending.gov.

About this award

The Department of the Interior Departmental Offices awarded Cooperative Agreement D26AC50003 to The Salk Institute For Biological Studies on February 23, 2026, obligating $7.620641 million under the Advanced Research Projects Agency for Health (ARPA-H) program to develop a sonogenetic platform technology that avoids off-target and systemic side effects of drug-based treatments by using ultrasound-based methods to alleviate symptoms of clinically relevant indications in mice and large animal models.

Work is performed in La Jolla, California with a period of performance through August 22, 2027. ARPA-H (CFDA 93.384) supports discovery and translation of revolutionary scientific breakthroughs into transformative health technologies, creation of platform capabilities drawing on multiple disciplines, and acceleration of transformational health advances in areas with limited technical certainty.

The Salk Institute passes work to three sub-recipients. Scripps Research Institute screens for new mechanosensitive proteins. The University of Manitoba designs and executes proof-of-concept experiments in agreed-upon clinical indications for existing channels and evaluates new sonochannels in proof-of-concept experiments. Sononeu, Inc., performs analysis and selection of clinical indications for sonogenetics approaches, provides experimental validation of clinical indications, models ultrasound stimuli in a water tank, and manages regulatory compliance, legal, data management, and intellectual property tasks toward pre-IND and commercialization. All three sub-awards were issued August 26, 2026.

Description

This project platform will mitigate current drug-based treatments' limitations by avoiding off-target and systemic side effects while providing a novel, scalable approach to clinical applications with unparalleled precision and safety. A sonogenetic method will be used to alleviate symptoms of a clinically relevant indication in mice and large animal models.

Transactions

Action Obligated Date
Amendment $0
Original award $7,620,641

Subawards

Subrecipient Amount Awarded
The University Of Manitoba Design and execute proof-of-concept experiments in agreed-upon clinical indications for existing channels and to evaluate new sonochannels in proof-of-concept… $555,450
Sononeu, Inc. 1. To analysis and selection of clinical indications for sonogenetics approaches 2. Provide experimental validation of clinical indications for sonogenetics… $714,939
Scripps Research Institute To screen for new mechanosensitive proteins. $2,121,912

Quick answers

Who received award D26AC50003?

D26AC50003 was awarded to The Salk Institute For Biological Studies. San Diego. California by Interior Business Center (Office of Policy Management and Budget) on February 23, 2026.

How much is award D26AC50003 worth?

$7,620,641 has been obligated on D26AC50003.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award